Abstract
MicroRNAs (miRNAs) are emerging as important regulators in various pathobiological processes in cancer. Genistein, as a major isoflavonoid isolated from dietary soybean, possesses a wide variety of biological activities particularly in cancer prevention. However, the molecular mechanisms by which genistein elicits its effects on ovarian cancer cells have not been fully elucidated. In this study, we reported that expression of miR-27a was higher in human ovarian cancer relative to benign ovarian tissues. Meanwhile, transfection of SKOV3 cells with the inhibitor of miR-27a suppressed growth and migration of tumor cells. Our study also found that treatment of ovarian cancer cells with genistein caused an inhibition of ovarian cancer cell growth and migration. Further cellular mechanistic studies revealed that genistein down-regulated miR-27a expression, which was accompanied by significantly increased expression of Sprouty2, a putative miR-27a target gene. Taken together, our findings reveal that oncogenic miR-27a plays an important role in ovarian cancer cell growth and metastasis, and genistein, as nontoxic inactivators of miRNA, can block ovarian cancer cell growth and migration, offering novel insights into the mechanisms of genistein therapeutic actions.
Keywords: Genistein, Ovarian cancer, microRNA-27a (miR-27a), Target gene, Sprouty2, SKOV3.
Anti-Cancer Agents in Medicinal Chemistry
Title:Oncogenic MicroRNA-27a is a Target for Genistein in Ovarian Cancer Cells
Volume: 13 Issue: 7
Author(s): Linlin Xu, Jingying Xiang, Jian Shen, Xi Zou, Sulan Zhai, Yongxiang Yin, Ping Li, Xuerong Wang and Qingmin Sun
Affiliation:
Keywords: Genistein, Ovarian cancer, microRNA-27a (miR-27a), Target gene, Sprouty2, SKOV3.
Abstract: MicroRNAs (miRNAs) are emerging as important regulators in various pathobiological processes in cancer. Genistein, as a major isoflavonoid isolated from dietary soybean, possesses a wide variety of biological activities particularly in cancer prevention. However, the molecular mechanisms by which genistein elicits its effects on ovarian cancer cells have not been fully elucidated. In this study, we reported that expression of miR-27a was higher in human ovarian cancer relative to benign ovarian tissues. Meanwhile, transfection of SKOV3 cells with the inhibitor of miR-27a suppressed growth and migration of tumor cells. Our study also found that treatment of ovarian cancer cells with genistein caused an inhibition of ovarian cancer cell growth and migration. Further cellular mechanistic studies revealed that genistein down-regulated miR-27a expression, which was accompanied by significantly increased expression of Sprouty2, a putative miR-27a target gene. Taken together, our findings reveal that oncogenic miR-27a plays an important role in ovarian cancer cell growth and metastasis, and genistein, as nontoxic inactivators of miRNA, can block ovarian cancer cell growth and migration, offering novel insights into the mechanisms of genistein therapeutic actions.
Export Options
About this article
Cite this article as:
Xu Linlin, Xiang Jingying, Shen Jian, Zou Xi, Zhai Sulan, Yin Yongxiang, Li Ping, Wang Xuerong and Sun Qingmin, Oncogenic MicroRNA-27a is a Target for Genistein in Ovarian Cancer Cells, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (7) . https://dx.doi.org/10.2174/18715206113139990006
DOI https://dx.doi.org/10.2174/18715206113139990006 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Natural compound-derived epigenetic regulators targeting epigenetic readers, writers and erasers
Current Topics in Medicinal Chemistry Astragalin Attenuates UVB Radiation-induced Actinic Keratosis Formation
Anti-Cancer Agents in Medicinal Chemistry The Need for Improvement of the Treatment of Advanced and Metastatic Cervical Cancer, the Rationale for Combined Chemo-Immunotherapy
Anti-Cancer Agents in Medicinal Chemistry Strategies for Targeting the Multidrug Resistance-1 (MDR1)/P-gp Transporter in Human Malignancies
Current Cancer Drug Targets Cancer Stem-Cells Patents in the Context of their Therapeutic Purposes: Exploring the Latest Trends (2011-2015)
Recent Patents on Regenerative Medicine Selective Gene Amplification for High-Throughput Sequencing
Recent Patents on DNA & Gene Sequences Targeting p73 - a Potential Approach in Cancer Treatment
Current Pharmaceutical Design The Role of Diabetes in Molecular Pathogenesis of Cancer
Current Signal Transduction Therapy Points of Therapeutic Intervention Along the Wnt Signaling Pathway in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Asialoglycoprotein Receptor and Glycyrrhetinic Acid Receptor-Mediated and/or pH-Responsive Hepatocellular Carcinoma- Targeted Drug Delivery
Current Medicinal Chemistry Synergistic Effect of α-Solanine and Cisplatin Induces Apoptosis and Enhances Cell Cycle Arrest in Human Hepatocellular Carcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Osteoclast Apoptosis in Rheumatic Diseases Characterized by a High Level of Bone Resorption (Osteoporosis, Rheumatoid Arthritis, Myeloma and Pagets Disease of Bone)
Current Rheumatology Reviews The PIK3CA Gene as a Mutated Target for Cancer Therapy
Current Cancer Drug Targets Lysophosphatidic Acid and Renal Fibrosis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Impact of Magnetic Nanoparticles in Biomedical Applications
Recent Patents on Drug Delivery & Formulation Recent Developments in Taxane Drug Delivery
Current Drug Delivery lGnRH-III - a Promising Candidate for Anticancer Drug Development
Protein & Peptide Letters Targeting Cancer Stem Cells Pathways for the Effective Treatment of Cancer
Current Drug Targets Advances in Cancer Stem Cell Therapy: Targets and Treatments
Recent Patents on Regenerative Medicine